Expression and significance of the TLR4/MyD88 signaling pathway in ovarian epithelial cancers

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Kim, Ki H ^a,b   Jo, Moo S ^c   Suh, Dong S ^a,b   Yoon, Man S ^a,b   Shin, Dong H ^a,d   Lee, Jeong H ^d   Choi, Kyung U ^a,d  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Pusan National University   (South Korea)

^d Pusan National University Yangsan Hospital   (South Korea)

Author keywords

MyD88; Ovarian epithelial cancer; Toll like receptor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CLINICAL FEATURE; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS; OVARIAN EPITHELIAL CANCER; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NF-KAPPA B; OVARIAN NEOPLASMS; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TOLL-LIKE RECEPTOR 4; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84866165676     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-193     Document Type: Article

References (22)

1. Yu L, Chen S. Toll-like receptors expressed in tumor cells: Targets for therapy. Cancer Immunol Immunother 2008, 57:1271-1278. 10.1007/s00262-008-0459-8, 18256828.
2. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: A double-edged sword. Oncogene 2008, 27:218-224. 10.1038/sj.onc.1210904, 18176603.
3. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009, 9:57-63. 10.1038/nrc2541, 19052556.
4. Akira S. Toll-like receptor signaling. J Biol Chem 2003, 278:38105-38108. 10.1074/jbc.R300028200, 12893815.
5. Naugler WE, Sakurai T, Kim S, Maeda S, Kim A, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124. 10.1126/science.1140485, 17615358.
6. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127. 10.1126/science.1140488, 17615359.
7. Fukata M, Abreu MT. Role of toll-like receptors in gastrointestinal malignancies. Oncogene 2008, 27:234-243. 10.1038/sj.onc.1210908, 2821878, 18176605.
8. Yu L, Wang L, Chen S. Toll-like receptors, inflammation and tumor in the human female reproductive tract. Am J Reprod Immunol 2009, 62:1-8. 10.1111/j.1600-0897.2009.00712.x, 19527227.
9. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868. 10.1158/0008-5472.CAN-05-3948, 16585214.
10. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000, 60:4693-4696.
11. Zhang JJ, Wu HS, Wang L, Tian Y, Zhang JH, Wu HL. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J Gastroenterol 2010, 16:2881-2888. 10.3748/wjg.v16.i23.2881, 2887583, 20556833.
12. Cheng I, Plummer SJ, Casey G, Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 16:352-355. 10.1158/1055-9965.EPI-06-0429, 17301271.
13. Song C, Chen LZ, Zhang RH, Yu XJ, Zeng YX. Functional variant in the 3'-untranslated region of toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther 2006, 5:1285-1291. 10.4161/cbt.5.10.3304, 16969132.
14. El-Omar EM, Ng MT, Hold GL. Polymorphisms in toll-like receptor genes and risk of cancer. Oncogene 2008, 27:244-252. 10.1038/sj.onc.1210912, 18176606.
15. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T. High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 2010, 102:908-915. 10.1038/sj.bjc.6605558, 2833250, 20145615.
16. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother 2009, 58:1375-1385. 10.1007/s00262-008-0650-y, 19184006.
17. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88:2584-2589. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5, 10861437.
18. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008, 99:653-658. 10.1111/j.1349-7006.2008.00747.x, 18377417.
19. Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002, 93:723-728. 10.1111/j.1349-7006.2002.tb01312.x, 12079522.
20. Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC. DNA repair protein levels vis-a-vis anticancer drug resistance in the human tumor cell lines of the national cancer institute drug screening program. Anticancer Drugs 2002, 13:511-519. 10.1097/00001813-200206000-00010, 12045463.
21. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436. 10.1038/nature04870, 16724054.
22. Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 2010, 116:3276-3284. 10.1002/cncr.25190, 2946598, 20564628.